Source-grounded facts extracted from Annexon, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Annexon, Inc. shareholders approved Amendment to certificate of incorporation to increase authorized shares from 300,000,000 to 500,000,000 at the 2026-06-11 meeting.
“The approval of an amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000. For Against Abstain Broker Non-Votes 129,051,256 4,374,799 8,795,454 —”
Annexon, Inc. shareholders approved Advisory (non-binding) approval of named executive officer compensation at the 2026-06-11 meeting.
“The approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 122,347,513 1,986,387 68,794 17,818,815”
Annexon, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm at the 2026-06-11 meeting.
“The ratification of the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified by the votes indicated. For Against Abstain Broker Non-Votes 142,016,122 185,546 19,841 —”
Annexon, Inc. shareholders approved Election of Class III directors at the 2026-06-11 meeting.
“The following two Class III directors were elected by the votes indicated. For Withheld Broker Non-Votes Bettina M. Cockroft, M.D. 101,594,745 22,807,949 17,818,815 Douglas Love, Esq. 107,491,451 16,911,243 17,818,815”
Annexon, Inc. reported first quarter ended March 31, 2026 results: net income $44.1 million or $0.23 per share, EPS $0.23 per share.
“March 31, 2025. The change in G&A expenses reflects ongoing corporate consulting and professional services costs. • Net loss: Net loss attributable to common stockholders was $44.1 million or $0.23 per share for the quarter ended March 31, 2026, compared to $54”
Annexon, Inc. reported financial results for the fourth quarter and the year ended December 31, 2025.
“On March 30, 2026, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2025.”
William Jones was appointed as Director at Annexon, Inc..
“On January 9, 2025, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed William Jones, to the Board, effectively immediately.”
Annexon, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 13, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2024.”
Annexon, Inc. reported financial results for fourth quarter and the year ended December 31, 2023.
“On March 26, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2023.”
Annexon, Inc. entered into Form of Pre-Funded Warrant with Certain investors valued at Pre-funded warrants to purchase up to 18,379,861 shares of common stock at $0.001 exercise price per (effective 2023-12-20).
“in lieu of Common Stock, certain investors were issued pre-funded warrants to purchase an aggregate of 18,379,861 shares of Common Stock at a price of $2.879 (the “ Pre-Funded Warrants ”), which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant”
Annexon, Inc. entered into Underwriting Agreement with Jefferies LLC and Cowen and Company, LLC valued at $125,000,000 gross proceeds; 25,035,000 shares of common stock at $2.880 per share and pre-funded wa (effective 2023-12-20).
“On December 20, 2023, Annexon, Inc. (the “ Company ’) entered into an underwriting agreement (“ Underwriting Agreement ”) with Jefferies LLC and Cowen and Company, LLC (the “ Underwriters ”), to issue and sell 25,035,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) at a price of $2.880 per share and, in lieu of Common Stock, certain investors were issued pre-funded warrants to purchase an aggregate of 18,379,861 shares of Common Stock at a price of $2.879 (the “ Pre-Funded Warrants ”), which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant (the “ Offering ”).”
Annexon, Inc. entered into Underwriting Agreement with Jefferies LLC and Cowen and Company, LLC valued at approximately $125.0 million (effective 2023-12-20).
“On December 20, 2023, Annexon, Inc. (the “C ompan y’) entered into an underwriting agreement (“ Underwriting Agreement ”) with Jefferies LLC and Cowen and Company, LLC (the “ Underwriters ”), to issue and sell 25,035,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) at a price of $2.880 per share”
Annexon, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023, EPS $0.47 per share.
“Annexon, Inc. (the “Company”) announced certain financial results for the second quarter ended June 30, 2023.”
Annexon, Inc. shareholders approved Advisory (non-binding) approval of the compensation of the Company's named executive officers at the 2023-06-08 meeting.
“Item 5.07. Submission of Matters to a Vote of Security Holders. Annexon, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on June 8, 2023. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. 1. The election of three nominees to serve as Class III directors for a three-year term to expire at the 2026 annual meeting of stockholders. The following three Class III directors were elected by the votes indicated. For Withheld Broker Non-Votes Bettina M. Cockroft, M.D. 43,699,076 120,214 2,916,664 Douglas Love, Esq. 43,698,406 120,884 2,916,664 Thomas G. Wiggans 32,454,366 11,364,924 2,916,664 2. The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The selection”
Annexon, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“Item 5.07. Submission of Matters to a Vote of Security Holders. Annexon, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on June 8, 2023. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. 1. The election of three nominees to serve as Class III directors for a three-year term to expire at the 2026 annual meeting of stockholders. The following three Class III directors were elected by the votes indicated. For Withheld Broker Non-Votes Bettina M. Cockroft, M.D. 43,699,076 120,214 2,916,664 Douglas Love, Esq. 43,698,406 120,884 2,916,664 Thomas G. Wiggans 32,454,366 11,364,924 2,916,664 2. The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The selection”
Annexon, Inc. shareholders approved Election of three nominees to serve as Class III directors at the 2023-06-08 meeting.
“Item 5.07. Submission of Matters to a Vote of Security Holders. Annexon, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on June 8, 2023. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. 1. The election of three nominees to serve as Class III directors for a three-year term to expire at the 2026 annual meeting of stockholders. The following three Class III directors were elected by the votes indicated. For Withheld Broker Non-Votes Bettina M. Cockroft, M.D. 43,699,076 120,214 2,916,664 Douglas Love, Esq. 43,698,406 120,884 2,916,664 Thomas G. Wiggans 32,454,366 11,364,924 2,916,664 2. The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The selection”
Annexon, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss was $38.7 million or $0.52 per share.
“On May 8, 2023, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2023.”
Annexon, Inc. reported fourth quarter and the year ended December 31, 2022 results: net income Net loss was $34.4 million for the quarter ended December 31, 2022, and $141.9 million for the year ended December 31, 2.
“On March 6, 2023, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2022.”
Larry C. Mattheakis departed as Chief Scientific Officer at Annexon, Inc..
“Dr. Artis is succeeding Larry C. Mattheakis, Ph.D., who is departing from the Company and is no longer serving as Chief Scientific Officer effective as of January 6, 2023.”
Dean Richard Artis was appointed as Chief Scientific Officer at Annexon, Inc..
“the appointment of Dean Richard Artis, Ph.D. as Chief Scientific Officer of the Company.”
Annexon, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022, EPS $0.51 per share.
“Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported third quarter 2022 financial results.”
Ricky Sun resigned as Director at Annexon, Inc..
“On February 1, 2022, Ricky Sun, Ph.D., notified the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) of his decision to resign from the Board, effective immediately.”
Bettina M. Cockroft was appointed as Director at Annexon, Inc..
“On January 19, 2022, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., to the Board, effectively immediately.”
Larry Mattheakis was appointed as Chief Scientific Officer at Annexon, Inc..
“Larry Mattheakis, Ph.D. as Chief Scientific Officer”
Ted Yednock was appointed as Chief Innovation Officer at Annexon, Inc..
“appointed Ted Yednock, Ph.D. as Chief Innovation Officer”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.